Evaluation of the effect and safety of recombinant human erythropoietin (ior (R)EPOCIM ) as a cardioprotective agent in the surgery of rheumatic valvular disease.
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Rheumatic disorders
- Focus Adverse reactions
- 29 Aug 2016 New trial record